Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | CCR5 | P51681 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | CCR3 | P51677 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4777069 | 0.86 | CCR5 (0.68) | GAAKDM4ELMNACCR5OPRM1 | |
| SCHEMBL4773843 | 0.86 | OPRM1 (0.49) | GAAKDM4ELMNACCR5OPRM1 | |
| Trifluoroacetic Acid SCHEMBL4773894 | 0.85 | CCR5 (0.55) | GAAKDM4ELMNACCR5OPRM1 | |
| Trifluoroacetic Acid SCHEMBL4775516 | 0.85 | GAA (0.55) | GAAKDM4ELMNACCR5OPRM1 | |
| Trifluoroacetic Acid SCHEMBL4768574 | 0.83 | CCR5 (0.63) | GAAKDM4ELMNACCR5OPRM1 | |
| Trifluoroacetic Acid SCHEMBL4777815 | 0.83 | CCR5 (0.63) | GAAKDM4ELMNACCR5OPRM1 | |
| Trifluoroacetic Acid SCHEMBL4778140 | 0.82 | CCR5 (0.60) | GAAKDM4ELMNACCR5OPRM1 | |
| Trifluoroacetic Acid SCHEMBL4775779 | 0.82 | CCR5 (0.64) | GAAKDM4ELMNACCR5OPRM1 | |
| SCHEMBL7163438 | 0.80 | OPRM1 (0.47) | GAAKDM4ELMNACCR5OPRM1 | |
| SCHEMBL6056771 | 0.80 | OPRM1 (0.53) | OPRM1CCR3SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348324-B2 | Cyclic amine compounds as CCR5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-25 | — | — | US | disclosed |
| EP-1886994-A1 | Cyclic amine compounds as CCR5 antagonists | Takeda Pharmaceutical Company Limited (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | GAA 4215/4885KDM4E 2791/4885LMNA 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.